Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Promising Malaria Drug Created at Rutgers to Undergo Clinical Trials

3/11/2016

0 Comments

 
New Brunswick, NJ ― Todd B. Bates reports that malaria killed about 440,000 people – mostly young children – last year, but a new drug candidate discovered at Rutgers may help fight the long-dreaded disease.
 
The compound, which literally blows up malaria parasites in the blood stream, is about to undergo clinical trials, said Spencer Knapp, a chemistry professor in the Department of Chemistry and Chemical Biology at Rutgers University-New Brunswick.
 
“That’s actually a very exciting development,” said Knapp, who has been at Rutgers for 38 years and works in the School of Arts and Sciences.  “The drugs that are out there are starting to encounter resistance, so this is a new drug candidate just now entering trials. We don’t know how effective it will be yet in humans.”
​The compound, code-named SJ733, works in a novel way, said Knapp, who first prepared the chemical in his lab.
 
It binds to a malaria parasite protein that serves as a sodium (salt) pump. The pump is designed to get rid of sodium, but the compound blocks or interferes with the protein, and sodium ions build up.  That allows water to rush in, blowing up the parasite inside human blood cells.
 
“It’s really quite interesting,” he said, noting that Rutgers is co-holder (with St. Jude Children’s Research Hospital in Memphis, Tennessee, and Medicines for Malaria Venture in Geneva) of a U.S. patent that is pending.
 
Malaria, a mosquito-borne disease, can make people very sick. Fever, chills and flu-like illness are common symptoms, according to the U.S. Centers for Disease Control and Prevention. More severe cases of malaria can lead to seizures, coma, severe anemia, acute respiratory distress, kidney failure and other problems.
 
The United States was deemed malaria-free in 1949, according to the CDC.
 
But last year, an estimated 214 million people worldwide contracted malaria, according to the World Health Organization. The scourge is particularly lethal to children under five, who accounted for 70 percent of the roughly 440,000 deaths.
 
Africa is essentially ground-zero for malaria. Last year, 88 percent of malaria cases and 90 percent of deaths linked to the disease were there, according to WHO.
 
Still, malaria cases and deaths have dropped a lot in recent years. Between 2000 and 2015, new malaria cases fell by 37 percent globally and 42 percent in Africa, according to WHO. Malaria death rates plunged by 60 percent globally and 66 percent in Africa.
 
Three key reasons are greater use of insecticide-treated mosquito nets, indoor spraying and artemisinin-based combination therapies. The latter medicines are very effective against P. falciparum, the deadliest and most common malaria parasite.
 
According to Knapp, the National Institutes of Health awarded $1.5 million to Rutgers over five years as part of a collaborative effort to fight malaria.
 
Aside from Knapp, the lead scientists include: James Duffy of the Medicines for Malaria Venture (MMV) in Geneva, Switzerland; R. Kiplin Guy at St. Jude Children’s Research Hospital; and David M. Floyd of MMV and a Rutgers consultant.
 
St. Jude, MMV and Eisai Inc. have been working to deliver the preclinical studies and clinical trials through phase 2, according to Knapp, with funding from the Global Health Innovation Technology Fund.
 
Large amounts of SJ733 — 4 kilograms, or 8.8 pounds — were synthesized by contract for the clinical trials, he said.
 
The compound has been tested successfully in preclinical safety studies, with no side effects detected so far.  “There are plenty of compounds that don’t make it through animal studies, but ours has made it through,” Knapp said.
 
The clinical trials could last as long as two years, he said. During phase 1, SJ733 — in the form of pills — will be given to healthy volunteers to assess the safety and pharmacokinetics of the compound. Pharmacokinetics refers to how drugs are absorbed, distributed, metabolized and eliminated by the body, according to the National Institutes of Health.
 
Then SJ733 would be tested in two phases of human malaria studies to find out if it works and if it’s safe.
 
“The thing about malaria is that really, really poor people have it, so the medicine has to be very inexpensive,” Knapp said. “We think that ours is going to be inexpensive.”
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507